OLIKOS Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients who Transition from Intravenous Anti-CD20 Therapy

被引：0
|
作者：
Hua, Le H. [1 ]
Alvarez, Enrique [2 ]
Foley, John [3 ]
Henry, Roland G. [4 ]
Brown, Joel [5 ]
Camacho, Elizabeth [5 ]
Meng, Xiangyi [5 ]
Ziehn, Marina [6 ]
Brown, Brandon [5 ]
Greenberg, Benjamin M. [7 ]
机构：
[1] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA
[2] Univ Colorado, Boulder, CO 80309 USA
[3] Rocky Mt Multiple Sclerosis Clin, Salt Lake City, UT USA
[4] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA
[5] Novartis Pharmaceut, Basel, Switzerland
[6] Novartis Pharma AG, Basel, Switzerland
[7] UT Southwestern Med Ctr, Dallas, TX USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4567
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
    Fox, Edward
    Lovett-Racke, Amy E.
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Cocozza, Sirio
    Shubin, Richard
    Wray, Sibyl
    Weiss, Michael S.
    Bosco, Jenna A.
    Power, Sean A.
    Mok, Koby
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
  • [22] Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy
    Koc, Emine Rabia
    Turan, Omer Faruk
    Saridas, Furkan
    Menguc, Bedirhan
    Minaz, Sema Nur
    Ozkaya, Guven
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2023, 26 (05) : 697 - 701
  • [23] Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
    Coiffier, Bertrand
    Lepretre, Stephane
    Pedersen, Lars Moller
    Gadeberg, Ole
    Fredriksen, Henrik
    van Oers, Marinus H. J.
    Wooldridge, James
    Kloczko, Janusz
    Holowiecki, Jerzy
    Hellmann, Anrzej
    Walewski, Jan
    Flensburg, Mimi
    Petersen, Jorgen
    Robak, Tadeusz
    BLOOD, 2008, 111 (03) : 1094 - 1100
  • [24] Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials
    Quattrocchi, Emilia
    Ostergaard, Mikkel
    Taylor, Peter C.
    van Vollenhoven, Ronald F.
    Chu, Myron
    Mallett, Stephen
    Perry, Hayley
    Kurrasch, Regina
    PLOS ONE, 2016, 11 (06):
  • [25] Switching from intravenous to subcutaneous anti-CD20 mediated B cell depletion preserves memory B cells in patients with RRMS
    Haase, Stefanie
    Burner, Felix
    Freudenstein, David
    Angstwurm, Klemens
    Lee, De-Hyung
    Linker, Ralf
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 621 - 622
  • [26] Disease Modifying Therapy Choice in People with Multiple Sclerosis in The Era of Covid: Characterizing Outcomes in Patients who Switched from anti-CD20 Therapies to Diroximel Fumarate
    Kaczmarek, O.
    Sethi, A.
    Teng, E.
    Bumstead, B.
    Buhse, M.
    Zarif, M.
    Scott, N.
    Gocke, A.
    Mendoza, J. P.
    Gudesblatt, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 78 - 79
  • [27] Feasibility of strategic monitoring in patients with prior HBV exposure undergoing anti-CD20 monoclonal antibody therapy: a prospective observational study
    Seto, Wai-Kay
    Mak, Lung-Yi
    Liu, Sze Hang Kevin
    Cheung, Ka-Shing
    Fung, James
    Wong, Danny
    Lai, Ching-Lung
    Yuen, Man-Fung
    HEPATOLOGY, 2017, 66 : 1009A - 1009A
  • [28] Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa
    Konen, Franz Felix
    Pfeuffer, Steffen
    Jendretzky, Konstantin Fritz
    Gehring, Klaus
    Elias-Hamp, Birte
    Suehs, Kurt-Wolfram
    Pawlitzki, Marc
    Meuth, Sven
    Kleinschnitz, Christoph
    Pul, Refik
    Skripuletz, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 328 - 330
  • [29] An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
    RA Eisenberg
    S Khan
    J Stansberry
    D Tsai
    S Kolasinski
    E Rieder
    B Kotzin
    RJ Looney
    C Strieber
    D Albert
    Arthritis Res Ther, 6 (Suppl 3):
  • [30] Patient preference and time allocation assosiated with transition from intravenous to subcutaneus administration of natalizumab in patients with relapsing remitting MS - a questionnaire study
    Almroth, Anna
    Soderbarg, Karin
    Bostrom, Anna-Karin
    Sjoblom, Irina
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 379 - 379
12345